BR112012018703A2 - compostos e seus efeitos sobre o comportamento alimentar - Google Patents

compostos e seus efeitos sobre o comportamento alimentar

Info

Publication number
BR112012018703A2
BR112012018703A2 BR112012018703A BR112012018703A BR112012018703A2 BR 112012018703 A2 BR112012018703 A2 BR 112012018703A2 BR 112012018703 A BR112012018703 A BR 112012018703A BR 112012018703 A BR112012018703 A BR 112012018703A BR 112012018703 A2 BR112012018703 A2 BR 112012018703A2
Authority
BR
Brazil
Prior art keywords
compounds
effects
reduction
eating behavior
analogs
Prior art date
Application number
BR112012018703A
Other languages
English (en)
Inventor
Stephen Robert Bloom
Original Assignee
Imp Innovations Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imp Innovations Ltd filed Critical Imp Innovations Ltd
Publication of BR112012018703A2 publication Critical patent/BR112012018703A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65G—TRANSPORT OR STORAGE DEVICES, e.g. CONVEYORS FOR LOADING OR TIPPING, SHOP CONVEYOR SYSTEMS OR PNEUMATIC TUBE CONVEYORS
    • B65G23/00—Driving gear for endless conveyors; Belt- or chain-tensioning arrangements
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57545—Neuropeptide Y
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65G—TRANSPORT OR STORAGE DEVICES, e.g. CONVEYORS FOR LOADING OR TIPPING, SHOP CONVEYOR SYSTEMS OR PNEUMATIC TUBE CONVEYORS
    • B65G2812/00—Indexing codes relating to the kind or type of conveyors
    • B65G2812/02—Belt or chain conveyors
    • B65G2812/02267—Conveyors having endless traction elements
    • B65G2812/02277—Common features for chain conveyors
    • B65G2812/02287—Driving means
    • B65G2812/02306—Driving drums
    • B65G2812/02316—Driving drums with means for assuring constant linear speed of chains

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Mechanical Engineering (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

compostos e seus efeitos sobre o comportamento alimentar. a presente invenção refere-se a análagos de peptídeo de pyy, composições compreendendo os referidos análagos e métodos de uso dos referidos análagos para o tratamento e prevenção de distúrbios metabólicos, por exemplo, distúrbios de metabolismo de energia, tal como diabetes e obesiddae, e para uma redução no apetite, redução na ingestão de alimento oudredação de ingestão de caloria em um indivíduo.
BR112012018703A 2010-01-27 2011-01-27 compostos e seus efeitos sobre o comportamento alimentar BR112012018703A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1001333.2A GB201001333D0 (en) 2010-01-27 2010-01-27 Novel compounds and their effects on feeding behaviour
PCT/GB2011/000110 WO2011092473A1 (en) 2010-01-27 2011-01-27 Novel compounds and their effects on feeding behaviour

Publications (1)

Publication Number Publication Date
BR112012018703A2 true BR112012018703A2 (pt) 2017-01-10

Family

ID=42084054

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012018703A BR112012018703A2 (pt) 2010-01-27 2011-01-27 compostos e seus efeitos sobre o comportamento alimentar

Country Status (13)

Country Link
US (1) US9018160B2 (pt)
EP (1) EP2528942B1 (pt)
JP (1) JP2013518090A (pt)
KR (1) KR20120127610A (pt)
CN (1) CN102741278A (pt)
AU (1) AU2011210165B2 (pt)
BR (1) BR112012018703A2 (pt)
CA (1) CA2788013A1 (pt)
GB (1) GB201001333D0 (pt)
MX (1) MX2012008792A (pt)
RU (1) RU2012136530A (pt)
SG (1) SG182578A1 (pt)
WO (1) WO2011092473A1 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201101459D0 (en) 2011-01-27 2011-03-16 Imp Innovations Ltd Novel compounds and thier effects on fedding behaviour
SG11201508469YA (en) * 2013-05-02 2015-11-27 Glaxosmithkline Ip Dev Ltd Therapeutic peptides
WO2015177572A1 (en) 2014-05-23 2015-11-26 Imperial Innovations Limited Peptide yy (pyy) analogues
WO2015177573A1 (en) * 2014-05-23 2015-11-26 Imperial Innovations Limited Peptide yy (pyy) analogues
US10404205B2 (en) * 2015-08-04 2019-09-03 Goal Zero Llc Portable solar panel system
CN108473535A (zh) 2015-12-16 2018-08-31 饮食生活私人有限责任公司 膳食肽
GB201720188D0 (en) * 2017-12-04 2018-01-17 Imperial Innovations Ltd Analogues of PYY
MX2020007410A (es) 2018-01-23 2020-11-09 Gila Therapeutics Inc Formulaciones, composiciones y métodos farmacéuticos de péptido yy.
GB2573145A (en) * 2018-04-26 2019-10-30 Univ Ulster Peptides for metabolic disease
GB201908426D0 (en) 2019-06-12 2019-07-24 Imp College Innovations Ltd Appetite suppressing compounds
CN115698053A (zh) 2020-04-17 2023-02-03 I2O治疗公司 长效酪酪肽(pyy)类似物和使用方法

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
CA1257199A (en) 1986-05-20 1989-07-11 Paul Y. Wang Preparation containing bioactive macromolecular substance for multi-months release in vivo
IT1243390B (it) 1990-11-22 1994-06-10 Vectorpharma Int Composizioni farmaceutiche in forma di particelle atte al rilascio controllato di sostanze farmacologicamente attive e procedimento per la loro preparazione.
EP0668910B1 (en) 1991-11-06 1999-05-26 Garvan Institute Of Medical Research Human neuropeptide y-y1 receptor
WO1995005848A1 (en) 1993-08-24 1995-03-02 Novo Nordisk A/S Protracted glp-1
US5907030A (en) 1995-01-25 1999-05-25 University Of Southern California Method and compositions for lipidization of hydrophilic molecules
US5962270A (en) 1996-02-06 1999-10-05 Bionebraska, Inc. Recombinant preparation of calcitonin fragments and use thereof in the preparation of calcitonin and related analogs
US6355478B1 (en) 1996-06-17 2002-03-12 Eli Lilly And Company Rhesus monkey neuropeptide Y Y2 receptor
US6093692A (en) 1997-09-25 2000-07-25 The University Of Southern California Method and compositions for lipidization of hydrophilic molecules
FR2774674B1 (fr) 1998-02-10 2000-03-24 Atochem Elf Sa Procede de preparation d'une solution aqueuse de peroxyde d'hydrogene directement a partir d'hydrogene et d'oxygene et dispositif permettant sa mise en oeuvre
US5993414A (en) 1998-04-23 1999-11-30 Medtronic, Inc. Implantable device
US6436091B1 (en) 1999-11-16 2002-08-20 Microsolutions, Inc. Methods and implantable devices and systems for long term delivery of a pharmaceutical agent
US6420352B1 (en) 2000-07-19 2002-07-16 W. Roy Knowles Hair loss prevention
WO2003026591A2 (en) 2001-09-24 2003-04-03 Imperial College Innovations Ltd. Modification of feeding behavior
US7186692B2 (en) 2002-12-17 2007-03-06 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery and non-infused administration of Y2 receptor-binding peptides and methods for treating and preventing obesity
US8076288B2 (en) 2004-02-11 2011-12-13 Amylin Pharmaceuticals, Inc. Hybrid polypeptides having glucose lowering activity
WO2005077072A2 (en) 2004-02-11 2005-08-25 Amylin Pharmaceuticals, Inc. Hybrid polypeptides with selectable properties
EP1789440A4 (en) * 2004-02-11 2008-03-12 Amylin Pharmaceuticals Inc REASONS FOR THE FAMILY OF PANCREATIC POLYPEPTIDES AND POLYPEPTIDES CONTAINING THEM
CA2556226A1 (en) 2004-02-11 2006-08-10 Amylin Pharmaceuticals, Inc. Amylin family peptides and methods for making and using them
US20090186811A1 (en) 2004-03-17 2009-07-23 Thue Schwartz Y2 Selective Receptor Agonists for Therapeutic Interventions
WO2005089790A2 (en) 2004-03-17 2005-09-29 7Tm Pharma A/S Y2/y4 selective receptor agonists for therapeutic interventions
BRPI0508935A (pt) 2004-03-17 2007-09-25 7Tm Pharmas As agonistas de receptor seletivo y4 para intervenções terapêuticas
EA011860B1 (ru) * 2004-03-17 2009-06-30 7ТиЭм ФАРМА А/С Селективные агонисты рецептора y2 для терапевтического воздействия
EP2631244A1 (en) 2004-10-08 2013-08-28 Amylin Pharmaceuticals, Inc. Amylin family polypeptide-6 (AFP-6) analogs and methods of making and using them
EP3000826A1 (en) 2004-12-13 2016-03-30 Amylin Pharmaceuticals, LLC Pancreatic polypeptide family motifs, polypeptides and methods comprising the same
WO2007022123A2 (en) 2005-08-11 2007-02-22 Amylin Pharmaceuticals, Inc. Hybrid polypeptides with selectable properties
GB0504857D0 (en) 2005-03-09 2005-04-13 Imp College Innovations Ltd Novel compounds and their effects on feeding behaviour
JP4629488B2 (ja) 2005-04-28 2011-02-09 本田技研工業株式会社 プラントを制御する制御装置
CA2614619A1 (en) 2005-07-11 2007-01-18 Nastech Pharmaceutical Company Inc. Formulations for enhanced mucosal delivery of pyy
EA014647B1 (ru) * 2005-08-11 2010-12-30 Амилин Фармасьютикалз, Инк. Гибридные полипептиды с селектируемыми свойствами
GB0613196D0 (en) 2006-07-03 2006-08-09 Imp Innovations Ltd Novel compounds and their effects on feeding behaviour
US20100279930A1 (en) 2007-07-09 2010-11-04 Stephen Robert Bloom Human pancreatic polypeptide (hpp) analogues and their effects on feeding behaviour
WO2009042922A2 (en) * 2007-09-27 2009-04-02 Amylin Pharmaceuticals, Inc. Peptide-peptidase inhibitor conjugates and methods of making and using same
EP2279204A1 (en) * 2008-05-16 2011-02-02 Novo Nordisk A/S Long-acting y2 and/or y4 receptor agonists

Also Published As

Publication number Publication date
WO2011092473A8 (en) 2012-08-02
CA2788013A1 (en) 2011-08-04
JP2013518090A (ja) 2013-05-20
CN102741278A (zh) 2012-10-17
US9018160B2 (en) 2015-04-28
SG182578A1 (en) 2012-08-30
KR20120127610A (ko) 2012-11-22
US20130023464A1 (en) 2013-01-24
GB201001333D0 (en) 2010-03-17
EP2528942B1 (en) 2020-06-17
MX2012008792A (es) 2012-11-29
RU2012136530A (ru) 2014-03-10
WO2011092473A1 (en) 2011-08-04
AU2011210165A1 (en) 2012-08-23
EP2528942A1 (en) 2012-12-05
AU2011210165B2 (en) 2014-06-05

Similar Documents

Publication Publication Date Title
BR112012018703A2 (pt) compostos e seus efeitos sobre o comportamento alimentar
BR112013018782A2 (pt) compostos e seus efeitos no comportamento alimentar
BR112012032816A2 (pt) composição farmacêutica de liberação controlada, e, métodos para reduzir o efeito alimentar de uma composição de liberação controlada, reduzir o período de tempo necessário para que seja alcançado um estado estável para a metformina, para aperfeiçoar a biodisponibilidade de uma forma de dosagem de liberação controlada de matriz
BR112014004890A8 (pt) Bactéria, composição farmacêutica, alimentícia ou de ração, e, uso da bactéria
ECSP088849A (es) Pirrolidinonas sustituidas de pieridinil como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa 1
BR112013011249A2 (pt) inibidores de ibat para tratamento de distúrbios metabólicos e condições relacionadas
BR112015022514A2 (pt) composições que compreendem selênio e uso das mesmas para o tratamento e prevenção de doença ou condições associadas à disfunção mitocondrial
CO6781465A2 (es) Composición farmacéutica, métodos de tratamiento y usos de la misma
CL2012001043A1 (es) Compuestos derivados de hexahidroindenopiridina y/o octahidrobenzoquinolina, inhibidores de 11ß-hidroxiesteroide deshidrogenasa 1 (hsd 1); composiciones farmaceuticas que comprenden a los compuestos; y uso de los compuestos para la preparacion de medicamentos para el tratamiento de trastornos metabolicos.
BR112014016810A8 (pt) composições e métodos para tratamento de distúrbios metabólicos
BR112013000537A2 (pt) composição aquosa contendo bromexina
CL2014000801A1 (es) Variante de factor 21 de crecimiento de fibroblasto humano (fgf21); composicion farmaceutica que lo comprende; y su uso para tratar diabetes tipo 2, obesidad, dislipidemia, sindrome metabolico o cualquier combinacion de los mismos.
ECSP11011278A (es) Composición farmacéutica que comprende derivados de glucopiranosil difenilmetano, forma farmacéutica de la misma, procedimiento para su preparación y usos de la misma para el control glucémico mejorado en un paciente.
DOP2007000078A (es) Derivados de ciclohexilpirazol-lactama como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa 1
BR112012020839A2 (pt) vacinas para uso na profilaxe e tratamento de doença de vírus da influenza
CR10402A (es) Inhibidores de 11-beta-hidroxiesteroide deshidrogenasa 1
CL2013002210A1 (es) Formulación prebiótica para consumo humano que comprende 2´-fucosilactosa, 3´-sialilactosa y 6´-sialilactosa, en que la cantidad en peso de 3´-sialilactosa es al menos igual de elevada que la cantidad de 2´-fucosilactosa; y método para modular o estimular la proliferación de bifidobacterias en el intestino humano.
BR112014006587A8 (pt) Composto compreendendo oligonucleotídeo que modula a expressão de gcgr, composição, bem como seu uso no tratamento ou prevenção de diabetes
BR112012005044B8 (pt) composição farmacêutica que compreende uma combinação de (rac)-tramadol·hcl e celecoxib
BRPI0908541B8 (pt) uso de panax quinquefolius ou uma fração do mesmo na ativação de respostas imunes inatas e adaptativas
BR112013029256A8 (pt) combinação farmacêutica para uso no tratamento de pacientes com diabetes tipo 2
BRPI0822069B8 (pt) método para preparação de um extrato de fruta de cardo leiteiro
ITTO20110627A1 (it) Composizione farmaceutica di combinazione e metodi per trattare diabete e patologie metaboliche
BRPI1009781A2 (pt) compostos para o tratamento de distúrbios metabólicos, composição farmacêutica que os compreende e uso dos mesmos
BR112014003640A2 (pt) métodos para perda de peso e composições cetogênicas

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]